Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
Ask The Pharmacist: Why Migraine Medications in Work Comp Deserve a Closer Review
Migraine headaches can be disabling, difficult to document and costly to treat. In workers’ compensation, they also create claim complexity when causation, medication choice or treatment progress is not clearly supported.
In-Network and Out-of-Network Trends
This analysis provides a comprehensive examination of prescription utilization across both in-network and out-of-network channels including retail pharmacies, mail-order services, and paper-based medical bill submissions. This dual-lens approach captures the full prescription landscape that extends beyond traditional pharmacy benefit management reporting, revealing critical cost and utilization patterns across all jurisdictions. While in-network channels demonstrate the real-time effectiveness of integrated clinical controls and cost management strategies, out-of-network data, often representing acute treatment episodes captured through medical bill review, exposes significant cost management opportunities and pricing anomalies. Together, these perspectives illuminate where pharmacy dollars are spent, how prescriptions are managed, and where targeted interventions can drive the greatest impact on both clinical outcomes and costs.
Beyond the Return Date
A return-to-work plan can be medically sound and still fall short. The employee may be released to return, restrictions may be documented and accommodations may be approved. But a return sustainable? The goal is to help employees return in a way that is sustainable.
What Causes Bodily Injury Claim Overpayments and How to Prevent Them
Learn why bodily injury claims are overpaid and how consistent demand evaluation improves negotiation outcomes and reduces claim leakage
Life After Amputation: Coordinating Advanced Recovery Options
Catastrophic case management supports amputation recovery by coordinating prosthetic planning, rehabilitation and practical resources for injured employees.
The Largest Nuclear Verdicts in Q2 2026: Social Inflation Continues to Hinder Casualty Lines
A new Financial Times feature explores the forces driving nuclear verdicts and how the industry is responding, with insights from Enlyte's Michele Hibbert.